<DOC>
	<DOC>NCT01297842</DOC>
	<brief_summary>Adult patients with ESBL-producing Gram negative infections are randomized to receive ertapenem or meropenem/imipenem. Clinical and microbiological responses between both groups are compared.</brief_summary>
	<brief_title>Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections</brief_title>
	<detailed_description>Ertapenem is active against ESBL-producing Gram negative bacteria. This study is conducted to determine if ertapenem is effective against ESBL-producing Gram negative infections similar to meropenem/imipenem.</detailed_description>
	<mesh_term>Gram-Negative Bacterial Infections</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<mesh_term>Imipenem</mesh_term>
	<mesh_term>Ertapenem</mesh_term>
	<criteria>Hospitalized patients aged &gt;18 years with documented ESBL +ve GNB infection Receive meropenem or imipenem/cilastatin as empiric antibiotic therapy Having been treated with meropenem or imipenem/cilastatin for longer than 72 hours Have active P. aeruginosa coinfection Pregnancy or breast feeding Allergy to carbapenems</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>